ERRa was one of the NRs that differentiated the UM cluster from the CM cluster, and is particularly important given its role as a therapeutic target in other cancers (particularly breast cancer) and the growing availability of ERRa-targeted therapeutics (30) including inverse agonists, which lower the receptor’s constitutive activity. This evidence concerns the gene ESRRA and breast carcinoma.